“Elevated leukocyte counts, particularly increased neutrophil counts, and decreased hemoglobin levels, are associated with severe WMHs,” according to Dr Liu’s team. “Our study results highlight the ...

In this video, Anjay Rastogi, MD, PhD, professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, discusses treatment options for chronic kidney disease patients with ...

Investigators assessed sex differences in the risk for major cardiovascular events (MACE+) among patients with anemia of non-dialysis chronic kidney disease (CKD).

Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter of 2025. The report is available on the company's website ...

Modus Therapeutics Holding AB (“Modus Therapeutics”) hereby publishes an interim report for the third quarter of 2025. The report is available on the company’s website ( and as an attachment to this ...

In this video, Anjay Rastogi, MD, PhD, professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, highlights necessary lifestyle adjustments for chronic kidney disease ...

Kidney disease disproportionately affects Black communities, with Black Americans nearly four times as likely to develop ...

Akebia Therapeutics has scrapped plans for a trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo, the company said. In March 2024, the FDA ...

The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe ...

CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

A study was conducted to determine the relationship between the severity of preprocedural anemia and outcomes following TAVR.

Akebia Therapeutics recently reported third-quarter 2025 revenue of US$58.77 million, up from US$37.43 million the previous year, and achieved net income of US$0.54 million after a prior net loss, ...